It was therefore approved by the FDA in December 2019 and by the European Medicines Agency (EMA) in January 2021 and is currently considered the standard treatment for patients with HER2+ metastatic BC after progression on dual HER2 blockade with a taxane and T-DM1 [10]. Here, ERBB2 is linked to breast cancer.